Key laboratory of T cell and immunotherapy was set up by Chinese academy of medical sciences (CAMS) in 2019. The key laboratory promotes basic research achievements applying in clinical therapy and tries to find out the best indication of γδT cells immune therapy by aids of patented technology. The final goal is to bring about the industrialization of T cell therapy technology and individualized precision medicine for tumor patients.

The laboratory focuses on development of new technology of clinical immunotherapeutic scheme and novel diagnostic method of precision medicine. Meanwhile, we also carry out preclinical research and clinical trials of tumor immunotherapy technology based on γδT cells. Since its establishment, the key laboratory has actively conducted clinical trials of T cells immunotherapy for late stages tumors, aiming to improve the transformation of scientific and

technological achievements. By using the patented diagnostic method, tumor patients who have the best indication can be selected. In this way, the efficiency of immune therapeutic cell transfusion could be significantly elevated. As a result, research on novel cell immunotherapeutic technologies for tumor based on γδT cells has been constantly carried forward in terms of combination of multiple therapies and of design of genetically engineered cells.

In 2022, our lab partnered with many hospitals to conduct clinical trials of γδT cells adoptive immunotherapy for cancer patients of advanced stage. In an project cooperated with the Fifth Medical Center of the General Hospital of the People's Liberation Army, autologous γδT cells were cultured in vitro and then transplanted back in 2 patients, proving that autologoustherapeutic regimenwas with good safety. Supported by the prophase data, clinical trial of allogeneic γδT cells transfusion has already been carried on.

Director: Jianmin Zhang

Staff:

Members: Hui Chen, Yu Hu, Yi Xu, Siya Zhang, Menghua Cai